These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 30593284)
1. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response. Francica P; Rottenberg S Genome Med; 2018 Dec; 10(1):101. PubMed ID: 30593284 [TBL] [Abstract][Full Text] [Related]
2. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics. Rabenau K; Hofstatter E Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114 [TBL] [Abstract][Full Text] [Related]
3. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252 [TBL] [Abstract][Full Text] [Related]
4. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Gourley C; BalmaƱa J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911 [TBL] [Abstract][Full Text] [Related]
5. Reverse the Resistance to PARP Inhibitors. Kim Y; Kim A; Sharip A; Sharip A; Jiang J; Yang Q; Xie Y Int J Biol Sci; 2017; 13(2):198-208. PubMed ID: 28255272 [TBL] [Abstract][Full Text] [Related]
9. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells. Senhaji Mouhri Z; Goodfellow E; Jean-Claude B BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities. Rajawat J; Shukla N; Mishra DP Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338 [TBL] [Abstract][Full Text] [Related]
11. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211 [TBL] [Abstract][Full Text] [Related]
12. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy. Shah AP; Patel CN; Sureja DK; Sanghavi KP Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451 [TBL] [Abstract][Full Text] [Related]
13. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance. Kanev PB; Atemin A; Stoynov S; Aleksandrov R Semin Oncol; 2024; 51(1-2):2-18. PubMed ID: 37714792 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of PARP inhibitor sensitivity and resistance. D'Andrea AD DNA Repair (Amst); 2018 Nov; 71():172-176. PubMed ID: 30177437 [TBL] [Abstract][Full Text] [Related]
15. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
16. Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies. Chen SH; Yu X Sci Adv; 2019 Apr; 5(4):eaav4340. PubMed ID: 30989114 [TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase activity and inhibition in cancer. Dulaney C; Marcrom S; Stanley J; Yang ES Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320 [TBL] [Abstract][Full Text] [Related]
18. Opinion: PARP inhibitors in cancer-what do we still need to know? Wicks AJ; Krastev DB; Pettitt SJ; Tutt ANJ; Lord CJ Open Biol; 2022 Jul; 12(7):220118. PubMed ID: 35892198 [TBL] [Abstract][Full Text] [Related]